Research Papers: Gerotarget (Focus on Aging):

Royal jelly promotes DAF-16-mediated proteostasis to tolerate β-amyloid toxicity in C. elegans model of Alzheimer’s disease

Xiaoxia Wang, Min Cao and Yuqing Dong _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:54183-54193. https://doi.org/10.18632/oncotarget.10857

Metrics: PDF 2132 views  |   HTML 2812 views  |   ?  


Xiaoxia Wang1, Min Cao1,2 and Yuqing Dong1,2

1 Department of Biological Sciences, Clemson University, Clemson, SC, USA

2 Institute for Engaged Aging, Clemson University, Clemson, SC, USA

Correspondence to:

Yuqing Dong, email:

Keywords: Alzheimer’s disease; royal jelly; β-amyloid; DAF-16; proteostasis; Gerotarget

Received: April 21, 2016 Accepted: July 07, 2016 Published: July 26, 2016


Numerous studies have demonstrated that dietary intervention may promote health and help prevent Alzheimer’s disease (AD). We recently reported that bee products of royal jelly (RJ) and enzyme-treated royal jelly (eRJ) were potent to promote healthy aging in C. elegans. Here, we examined whether RJ/eRJ consumption may benefit to mitigate the AD symptom in the disease model of C. elegans. Our results showed that RJ/eRJ supplementation significantly delayed the body paralysis in AD worms, suggesting the β-amyloid (Aβ) toxicity attenuation effects of RJ/eRJ. Genetic analyses suggested that RJ/eRJ-mediated alleviation of Aβ toxicity in AD worms required DAF-16, rather than HSF-1 and SKN-1, in an insulin/IGF signaling dependent manner. Moreover, RJ/eRJ modulated the transactivity of DAF-16 and dramatically improved the protein solubility in aged worms. Given protein solubility is a hallmark of healthy proteostasis, our findings demonstrated that RJ/eRJ supplementation improved proteostasis, and this promotion depended on the transactivity of DAF-16. Collectively, the present study not only elucidated the possible anti-AD mechanism of RJ/eRJ, but also provided evidence from a practical point of view to shed light on the extensive correlation of proteostasis and the prevention of neurodegenerative disorders.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10857